NCT00583674CompletedPhase 2
A Randomized, Double Blind, Multi-Center, Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Cisplatin & Capecitabine (CX) in Combination With AMG 386 or Placebo in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Amgen
- Enrollment
- 171
- Primary Endpoint
- Progression Free Survival (PFS)
Study Overview
Brief Summary
This is a phase 2, randomized, double blind, placebo controlled, multi-center study to estimate the improvement in progression free survival (compared to control subjects) and evaluate the safety and tolerability of AMG 386 in combination with Cisplatin & Capecitabine in the treatment of subjects with Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma. AMG 386 is a man-made medication that is designed to stop the development of blood vessels in cancer tissues. Cancer tissues rely on the development of new blood vessels, a process called angiogenesis, to obtain a supply of oxygen and nutrients to grow.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Disease Related
- •Histologically or cytologically confirmed adenocarcinoma of the stomach, gastroesophageal junction or distal esophagus with metastatic disease
- •Measurable or non-measurable disease per RECIST Guidelines
- •Prior gastrectomy (total or partial) may be allowed as long as subjects can take oral medications and meet all other inclusion/exclusion criteria. Subjects may not take crushed or dissolved capecitabine via a feeding/gastrostomy tube
- •Palliative radiotherapy for metastatic esophageal or gastric cancer prior to study entry may be allowed as long as all toxicities from radiotherapy have resolved and the radiotherapy was not to the only site of known metastatic disease
- •Demographic
- •18 years of age or older at the time the written informed consent is obtained
- •Able to swallow oral medication
- •ECOG performance status of 0 or 1
- •Laboratory
- •Adequate organ and hematological function as evidenced by laboratory studies prior to randomization
Exclusion Criteria
- •Disease Related
- •Prior chemotherapy for metastatic disease (1st line)
- •Less than 12 months have elapsed from completion of previous adjuvant or neoadjuvant chemotherapy or chemoradiotherapy
- •Subjects with persistent gastric outlet obstruction, complete dysphagia or feeding jejunostomy
- •Radiotherapy ≤ 14 days prior to randomization. Subjects must have recovered from all radiotherapy-related toxicities
- •Current or prior history of central nervous system metastases
- •History of arterial or deep venous thromboembolism within 12 months prior to randomization
- •History of bleeding diathesis or clinically significant bleeding within 6 months prior to randomization
- •Major surgical procedure within 28 days prior to randomization
- •Minor surgical procedure, placement of central venous access device or fine needle aspiration within 3 days prior to randomization
- •Prior malignancy except: malignancy treated with curative intent and without evidence of active disease for ≥ 3 years prior to randomization and felt to be at low risk for recurrence by treating physician, adequately treated non-melanomatous skin cancer or lentigo maligna without evidence of disease, adequately treated cervical carcinoma in situ without evidence of disease, prostatic intraepithelial neoplasia without evidence of prostate cancer
- •Prior malignancy (other than in situ cervical cancer, or basal cell cancer of the skin) unless treated with curative intent and without evidence of disease for ≥ 3 years prior to randomization
- •Clinically significant cardiovascular diseases within 12 months prior to randomization
- •Presence of clinically significant non-healing wound, ulcer (including gastrointestinal) or fracture as judged by the investigator
- •Ongoing or clinically significant active infection as judged by the investigator
- •Known hypersensitivity to bacterial proteins, or any of the drugs required in this study
- •Known peripheral neuropathy ≥Grade 1
- •Known dihydropyrimidine dehydrogenase deficiency
- •Known hypersensitivity to 5-FU/capecitabine
- •Known positive test for human immunodeficiency virus (HIV), hepatitis C, or hepatitis B surface antigen
- •Known active or chronic hepatitis
- •Medications
- •Currently or previously treated with angiopoietin inhibitors, or inhibitors of TIE-1 or TIE-2
- •Treatment with immune modulators such as cyclosporine or tacrolimus within 30 days prior to randomization
- •Treatment with sorivudine or its chemically related analogues
- •Anticoagulants (other than aspirin and anti-platelet agents) within 7 days prior to randomization. The concurrent use of low molecular weight heparin or heparanoids or low dose warfarin (i.e, ≤ 1 mg daily) for prophylaxis against thrombosis is acceptable while on study
- •Not yet completed at least 30 days since ending other investigational device/drug trial(s), or subject is receiving other investigational treatments
- •Pregnant or is breast feeding
Arms & Interventions
B
Experimental
Intervention: AMG 386 3mg/kg (Drug)
B
Experimental
Intervention: Cisplatin (Drug)
B
Experimental
Intervention: Capecitabine (Drug)
A
Experimental
Intervention: AMG 386 10mg/kg (Drug)
A
Experimental
Intervention: Cisplatin (Drug)
A
Experimental
Intervention: Capecitabine (Drug)
C
Active Comparator
Intervention: AMG 386 placebo (Drug)
C
Active Comparator
Intervention: Cisplatin (Drug)
C
Active Comparator
Intervention: Capecitabine (Drug)
Outcomes
Primary Outcomes
Progression Free Survival (PFS)
Time Frame: 22 months
Secondary Outcomes
- Safety and Tolerability(22 months)
- Objective Response Rate (ORR)(22 months)
- Duration of Response (DOR)(22 months)
- Overall Survival (OS)(22 months)
- Time to Progression (TTP)(22 months)
- Time to Response(22 months)
- Pharmacokinetics(22 months)
- Patient Reported Outcomes(22 months)
Investigators
Similar Trials
Completed
Phase 2
AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With SorafenibAdvanced Renal Cell CarcinomaNCT00467025Amgen152
Completed
Phase 2
Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal CancerFallopian Tube CancerPrimary Peritoneal CancerOvarian CancerNCT00479817Amgen161
Terminated
Phase 2
Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD)Pulmonary HypertensionChronic Obstructive Pulmonary DiseaseNCT01437878Actelion2
Completed
Phase 2
Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)NCT04906421Sagimet Biosciences Inc.168
Completed
Phase 2
A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-ThalassemiaThalassemiaNCT03342404Celgene145